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ABSTRACT 
  
OBJECTIVE: This study examined whether there were differences in the development 
of multiple primary cancers in lung cancer patients residing in the Appalachian versus Non-
Appalachian regions of Kentucky. The study also identified other factors associated with the 
development of another primary cancer in lung cancer patients. 
HYPOTHESIS: Lung cancer patients residing in Appalachian Kentucky are more likely 
to develop multiple primary cancers compared to patients residing in Non-Appalachian 
Kentucky. 
METHODS: This was a retrospective, population-based cohort study of Kentucky 
patients (N=26456) aged 20 years and older, diagnosed with primary lung cancer between 
January 1, 2000 and December 31, 2013. The study population was drawn from the Kentucky 
Cancer Registry. Cases were excluded if they were diagnosed with second primary cancers 
within 3 months after the diagnosis of their first primary lung cancer, and if they changed their 
residence moving from Appalachian to Non-Appalachian region or vice versa. Subjects were 
followed to determine if they developed subsequent primary cancers. The Cox proportional 
hazards model was used to control for the time from diagnosis to death or a second PC. 
RESULTS: The final adjusted multivariable hazards model indicated that there were no 
statistically significant differences between Kentucky Appalachian and Non-Appalachian lung 
cancer populations with respect to the hazards of developing of a subsequent primary cancer 
(HR: 1.002, p=0.9713). The adjusted analysis revealed that increasing age at diagnosis, male 
gender, and patients having surgery increased the hazards of developing another primary cancer 
(HR: 1.015, p=0.0001; 1.169, p=0.012; 1.446, p=0.0003). Having a stage IV tumor decreased the 
hazards of the outcome by 31.6% comparing to the patients with stage II tumors (HR=0.684, 
p=0.0015).  
CONCLUSION: No differences were found between Appalachian and Non-Appalachian 
lung cancer patients. Surgery was very likely associated with getting a second primary because 
patients who had surgery were likely to live longer, and thus, had a greater opportunity to 
develop a second primary. In contrast, patients who were diagnosed with stage IV lung cancer 
had very short survival times and were, thus, less likely to develop a second primary cancer. 
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I. INTRODUCTION  
1.1.  Objective of the Study. 
According to America’s Health Ranking, Kentucky is ranked 44th compared to all other 
U.S. states [1]. Kentucky residents have a high prevalence of smoking, obesity, diabetes, heart 
diseases, and cancers. The incidence and mortality rates for lung, breast, cervical and colorectal 
cancers are particularly high [2]. In 2012, Kentucky had the highest age-adjusted cancer incidence 
and mortality rates in the country compared to other U.S. states (515.1 and 201.2, per 100,000 
population respectively) [3]. During the time period 2000 through 2013 the age-adjusted 
incidence and mortality rates for all cancers in the state of Kentucky were (561.5 and 212.2). 
Significant differences in age-adjusted cancer incidence rates for the 2000-2013 time period can 
be observed between Kentuckians residing in Appalachian and Non-Appalachian regions (529.8 
versus 521.5) [4]. Cancer mortality rates also differ significantly between the Appalachian and 
Non-Appalachian areas of the state. Namely, age-adjusted cancer mortality rates for the period 
from 2000 through 2012 were much higher for those who reside in Appalachia Kentucky 
comparing to the Non-Appalachian area of the state (225.8 versus 191.6) [5].  
The existing literature postulates that improved clinical surveillance, including early 
screening and detection, has contributed to a decrease in cancer mortality. However, there has 
also been a notable increase in multiple primary malignancies among cancer patients, a 
phenomenon that has captured a lot of attention from clinicians and epidemiologists [6-8]. A 
number of factors may influence the risk of developing subsequent primary cancers, including 
genetic predisposition, environmental exposures, and the life style of individuals [6-13].  
For this study, Kentucky lung cancer patients were defined as the target population. Lung 
cancer is the leading cause of death and the second most commonly occurring cancer in both 
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men and women in the U.S. [14, 15]. Lung cancer incidence and mortality rates are notably 
higher in Kentucky than nationwide [16]. During 2007-2011, the age-adjusted incidence rate for 
lung cancer in Kentucky was 122.9 for men and 80.7 for women. These rates are higher than the 
estimated incidence rates for the nation as a whole during the same time period for men and 
women, respectively (78.6 and 54.6) [16]. The age-adjusted lung cancer mortality rates during 
2007-2011 were higher in Kentucky than in the US for both men and women, respectively (94.5 
and 55.5 vs. 61.6 and 38.5) [16].  
Within the state of Kentucky rates differ with respect to the region of residence. 
Specifically, during 2000-2013 the age-adjusted lung cancer incidence and mortality rates in the 
Appalachian region were higher than the rates in the Non-Appalachian region. The age-adjusted 
incidence rate in the Appalachian region was 109.8 per 100,000 persons, whereas the estimated 
incidence rate for lung cancer in the Non-Appalachian region for the same time period was 95.3 
per 100.000 persons [17]. The age-adjusted lung cancer mortality rate in the Appalachian region 
during 2000-2012 was 84.8 per 100,000 persons, whereas the estimated mortality rate for lung 
cancer in the Non-Appalachian region during this same time period was 64.9 per 100.000 persons 
[18].  
Smoking and exposure to environmental carcinogens are associated with an increased risk 
in lung cancer. Additionally, interactions of these exposure factors with a genetic predisposition 
may significantly increase the odds of developing a first lung cancer, and then another subsequent 
primary cancer [6, 19, 20]. Therefore, considering the high incidence and mortality rates of 
cancers in the state, and the existing environmental, socio-economic, and health-related 
differences between the Appalachian and Non-Appalachian regions, this study aimed to 
determine whether lung cancer patients from the Appalachian Kentucky developed subsequent 
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(second) primary cancers more frequently than lung cancer patients residing in the Non-
Appalachian area of the state. Also, this study tried to examine other factors associated with the 
development of subsequent primary cancers in patients first diagnosed with lung cancer.  
1.2.  Background. 
This study did not focus on examining subsequent primary cancers of the lung, but rather 
on development of subsequent primary cancers of any type, including secondary cancers of lung. 
Determining whether multiple lung tumors occur independently or due to the metastases has 
been an issue in lung cancer pathology. Studies describe cases of misdiagnosis of independent 
primaries appearing at the same time and tumors occurring due to metastases [21]. There are 
several reasons why the diagnosis of a second primary lung cancer is considered to be a complex 
issue. Difficulties exist in differentiating between metastatic and primary lesions if they occur 
within 2 years of the initial tumor. Differential diagnostics is also difficult if both the second 
primary lesion and initial tumor are of a similar histological subtype, and/or if the second lesion 
is located in the area of previous radiotherapy, since the latter leads to the changes in the tissue 
morphology [22]. 
The results of a voluntary survey of the Pulmonary Pathology Society showed that 
pathologists use different approaches to identify whether two anatomically distinct foci of lung 
carcinoma are intrapulmonary metastases or independent primaries [23]. Several studies 
described different methods of distinguishing whether multiple lung cancers occur due to 
metastases or patients have independent (in most cases, synchronous) primaries [21, 24, 25]. For 
instance, the diagnostic lineage test based on genomic rearrangements from mate-pair 
sequencing [24], the histologic-mutational methods, and the driver-mutational testing of selected 
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genes are recommended to be used for diagnosis of non-small synchronous cell lung cancers in 
patients with lymphatic metastases [26]. 
However, in most cases, a traditional method of diagnosis, known as Martini and 
Melamed criteria, is used. It is based on identifying tumor characteristics, i.e. morphology, 
location, presence or absence of carcinoma in situ, vascular invasion and metastasis. A number 
of studies described the increasing incidence of multiple primary lung cancers and issues related 
to their diagnosis, treatment and survival [26-38]. Previous research showed that the risk of 
developing multiple primary lung cancers ranges between 1 and 15 percent [22]. In most cases, 
multiple lung tumors are presented as secondary primary tumors, which can be synchronous or 
metachronous. It was indicated that synchronous multiple lung cancers had high occurrence in 
patients with idiopathic pulmonary fibrosis, who had the following characteristics: (1) male 
patients, (2) smokers, (3) had small cell carcinomas of (4) peripheral type in (5) lower lobes [27]. 
In contrast, according to Bhaskarla et al., a small proportion of lung cancer patients develop 
second primary lung cancers either synchronous or metachronous. In those patients, the 
reoccurrence was related to female gender, younger age, earlier stage, and white race [8].  
The risk of developing multiple primary cancers has been explored in various studies. 
Cancer patients can have multiple primary cancers detected in different sites, or they can occur in 
the same organ due to various exposures or genetic predisposition [39]. One study showed that 
there was a 2.2 times greater risk of developing a concordant secondary neoplasm, and 1.1 risk 
of developing a metachronous tumor of a different type and in another site [9]. The best 
explanation for these differences is that development of subsequent primary malignancies 
depends on the site of cancer as well as interactions of genetic predisposition and exposures that 
people may have [6].  
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The results of the analysis based data from the Surveillance, Epidemiology, and End 
Results (SEER) database have shown that the occurrence of multiple primary cancers varies 
depending on the site of origin. Namely, it ranges from the lowest 1 percent for an initial liver 
primary diagnosis to the highest of 16 percent for initial bladder cancer primaries. The highest 
percentages of reoccurrence or development of subsequent cancers of other sites were observed 
in patients with first primary cancers of urinary bladder, oral cavity and pharynx, kidney and 
pelvis, colon and rectum, melanoma of skin, prostate, and breast [7].  
According to these results, four percent of the patients who had the first primary cancer 
of the lung or other respiratory organs (including bronchus, trachea, mediastinum, and other 
organs) developed subsequent primary cancers. The median age at diagnosis of lung or other 
respiratory organs’ cancers was 67 years, and the 5-year observed survival rate for those lung 
cancer patients who developed multiple primaries was 11 percent [7]. 
Previous research showed that a number of factors are related to development of multiple 
primary cancers. They include effects from tobacco and alcohol consumption, infections, 
immunosuppression, genetic predisposition, and also effects of treatment of the initial cancer, the 
role of drug‑metabolizing enzymes, DNA repair proteins, and drug pharmacokinetics [6, 10].  
For instance, a systematic review of studies and meta-analysis looking at occurrence of 
second primary malignancy after radioactive iodine treatment for thyroid cancer revealed an 
increased risk of subsequent cancers (RR=1.19, 95% CI: 1.04-1.36) in those patients who 
received radioactive iodine treatment [40]. In general, the increased risk of such cancers as 
osteosarcomas, melanomas, and soft-tissue sarcomas is related to previously received 
radiotherapy [6]. 
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The association of surgical procedure and hazards of occurrence of another primary 
cancer has not been assessed by previous research. At the same time, it was found that aggressive 
surgical approach was beneficial for lung cancer patients with multiple synchronous lung lesions, 
and could positively affect patients’ survival rate [25, 28]. As indicated in the literature, 
development of subsequent primary cancers was positively associated with survival time (with 
the exception of thyroid cancer). Overall, the investigators concluded that, in order to develop 
multiple primary cancers, patients had to demonstrate relatively long survival after their initial 
diagnosis [7].  
Several factors were found to be related to the observed survival of cancer patients. 
Research shows that in lung cancer patients with non-small cell carcinomas, the risk of 
reoccurrence of cancer in the same site or development of a subsequent primary in another organ 
is not associated with a specific histologic type of tumors (i.e. squamous, adenocarcinomas) [41]. 
However, it was demonstrated that lung cancer patients with adenocarcinomas had better 
survival than patients with tumors of other histologic type, especially those with stage II cancers 
[42]. Also, female lung cancer patients with stage II tumors are known to have better survival 
compared to men [7]. This can be explained by a higher frequency of surgical procedures 
performed in women lung cancer patients, especially those with stage II tumors [7, 42].  
In fact, radiotherapy also increases survival in locally advanced non-small cell lung 
cancer patients who cannot tolerate surgical or drug treatments, especially if radiotherapy was 
combined with chemotherapy [43]. 
Associations of smoking and occurrence of second primary cancers have been discussed 
in the existing literature [6, 7]. A positive association of smoking and second primary cancers 
was identified among patients with head and neck squamous cell cancers [19]. Assessment of 
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standardized incidence ratios (SIRs) of subsequent primary cancers in all pairs of smoking-
associated cancers revealed that SIRs were much higher for women. This study also indicated 
that, in general, the magnitudes of the ratios are greater due to strong negative effects of smoking 
[20].   
Race and gender were found to be significant predictors of occurrence of subsequent 
primary cancers, with females and blacks having demonstrated larger odds of developing another 
primary cancer [6]. Namely, blacks had a higher risk of developing a second lymphoproliferative 
malignancy in patients with multiple myeloma [11], as well as ipsilateral or contralateral breast 
cancers [13]. However, whites were more likely to develop second primary lung [8], 
endometrial, and ovarian cancers [13], and both blacks and whites had greater odds of 
developing metachronous tumors as compared to representatives of other races among renal cell 
carcinomas survivors [12].  
Age is also an important factor. Koubkova et al., in a literature review, refer to the studies 
concluding that a huge burden of multiple primary malignancies was observed in the group of 
patients aged 30-59 years [6, 44], whereas one Czech study demonstrated that the highest burden 
of occurrence of subsequent cancers was observed in the older group – 50-69 years [6, 10]. 
Interestingly, patients who were cancer survivors during their childhood, had 6 times greater 
relative risks of developing a second primary cancer [6, 44].  
Therefore, we can note that a number of studies have explored the phenomenon of 
multiple primary malignancies in different cancer populations. However, there still is a need to 
examine various factors that may predict the occurrence of subsequent primary cancers in lung 
cancer patients, as this issue is not substantially described in the available literature. 
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1.3. Public Health Importance and Impact of the Study. 
No previous study has been conducted to compare whether there are differences in 
development of multiple primary cancers in lung cancer patients residing in Appalachian and Non-
Appalachian regions of Kentucky. The following research project is intended to address this 
question, and to describe other factors that impact and can predict the development of subsequent 
primary cancers in patients first diagnosed with lung cancer.  
1.4. Research Questions and Hypotheses. 
The objective of this study was to determine whether there were differences in the 
development of subsequent primary cancers among residents in Appalachian and Non-
Appalachian Kentucky who were first diagnosed with lung cancer, and assess which biological 
and demographic factors, as well as types of treatment (surgery or radiotherapy) that Kentucky 
lung cancer patients received, were associated with the development of another primary cancer.  
The primary hypothesis of the study was that lung cancer patients residing in Appalachia 
Kentucky were more likely to develop multiple primary cancers compared to patients residing in 
Non-Appalachia Kentucky. The reasoning behind this assumption was based on the fact that 
Appalachian Kentucky is characterized by a high prevalence of smoking rates, especially among 
males, as well as occupational and environmental exposure to coal-mining, low socio-economic 
status, lack of commercial health insurance coverage, and health professionals shortages [45, 46].  
1.5. Delimitations of the Study. 
This study had several delimitations. 
Firstly, the SEER database includes information about Educational Attainment, poverty 
level, and employment which is presented in the form of calculated percentages or rates based on 
Census tracts [47]. Since there was no individual level data, the investigators decided not to 
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include these variables in the analysis. Further research is recommended to assess the effect of 
these variables as potential residual confounders. 
Secondly, due to the nature and source of data, there were many missing values. The 
investigators decided to set those missing cases to separate groups, which were also included in 
the analysis. This was done in order not to exclude a large number of subjects, which would 
mean a loss of power. Imputing was not considered as an appropriate approach to address the 
issue of missing values for this particular study. 
Thirdly, increased incidence rates of many cancers are known to be attributed to older 
age [48]. As a result, a number of researchers either use stratification by age, or treat age as a 
categorical variable, so the differences between different age groups can be observed even 
assuming the loss of power for every additional cell. The range of age at which patients were 
diagnosed with their initial lung cancer was quite large, including patients from 21 to 100 years 
old. However, in this study, the investigators decided to treat age as a continuous variable, due to 
the fact that median age at diagnosis of lung cancer was 67 years, with first and third quartiles 
being 59 and 74 years, respectively. Thus, the majority of subjects would be included into the 
same age category. 
Fourthly, SEER data included a variable that expressed the sequence of received 
treatment for the initial lung cancer, showing whether radiation or surgery went first if a patient 
had both. Also, SEER data included a variable which showed the type of radiation a patient 
received. However, the investigators decided not to assess the dose-response effect of different 
radiation types, and not to account for the number or order of treatments that a patient could 
receive. At this point, there was no support from the reviewed literature that would have allowed 
for an adequate hypotheses to be made. Furthermore, there were many cases with missing 
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treatment information. This issue could be solved by linking SEER data to Medicaid or Medicare 
data. Thus, further investigations are suggested in order to address whether there are any 
associations between development of subsequent primary cancers with the sequence of treatment 
and/or dose-response effects of radiation.  
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II.  METHODOLOGY  
2.1.  Study design. Source of data. 
This was a retrospective, population-based cohort study using the SEER database was 
used for this research. The SEER Program of the National Cancer Institute collects data on 
cancer cases from a number of registries all over the U.S. beginning in 1973. Kentucky 
healthcare institutions and establishments also are required to report all cancer cases to the 
Kentucky Cancer Registry, which has participated in the SEER Program since 2000 [49].  
 To explore the phenomenon of multiple primary cancers, the SEER database was 
considered the best option. According to the SEER rules, recurrences or tumors of the same 
histology which are reported within 2 months, are excluded. Thus, there was no doubt in 
potential misclassification of primary cancers [7]. 
2.2.  Study subjects. Availability of data.  
Kentucky patients diagnosed with lung cancer as their first or the only primary from 
January 1, 2000 through December 31, 2013 were considered the target population for this study. 
Residence in Appalachian region of Kentucky was defined as the primary exposure.   
The study cohort included 47,166 of subjects with lung cancer, divided into two groups 
based on their residence status: Appalachian (15,780; 33.46%) or Non-Appalachian (31,386; 
66.54%) region of Kentucky. Among 47,166 lung cancer patients, 44,380 (94.09%) were 
diagnosed with lung cancer as their only primary, whereas 2,786 (5.91%) patients had lung 
cancer as their first primary, but later developed another primary cancer. The outcome of interest 
was the development of a second primary cancer after at least 3 months from the time of the 
diagnosis of lung cancer. This time frame was taken into consideration with the purpose to avoid 
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potential misclassification of the synchronous secondary cancer and a possible misclassification 
with metastasis. 
Identified cases were retrospectively followed during the observable survival time after 
their diagnosis of lung cancer in order to see if patients from Appalachian region were more 
likely to develop another primary cancer. In addition, this study examined other factors that 
could have impacted the development of subsequent cancers in lung cancer patients of Kentucky.  
To find out how many patients had developed further primary cancers, another SEER 
dataset was requested. It contained information on 41,883 subjects who were diagnosed with 
second primary cancers. Based on patient identification, after merging these two datasets (total 
of 86,721 subjects), it became possible to find out that 2,328 subject who were initially 
diagnosed with lung cancer as their first primary were present in both datasets, meaning that they 
eventually developed another cancer, whereas 44,380 subjects had only a single primary lung 
cancer.  
2.3.  Inclusion and Exclusion Criteria. 
The inclusion criteria were the following: 
• Kentucky lung cancer patients, who had lung cancer as their only or the first primary 
cancer, 
• patients aged twenty years and older, 
• malignant tumors only. 
The exclusion criteria were the following: 
• small or large cell carcinomas, 
• development of a subsequent primary cancer within 3 months, 
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• changing the place of residence moving from Appalachian to Non-Appalachian region or 
vice versa, 
• being initially coded as those having two or more primaries, but not having any records 
of developing another primary cancer. 
Therefore, this study included patients age twenty and older. All the subjects had 
malignant tumors. Patients (n=880) who were diagnosed with the second primary cancer within 3 
months after the diagnosis of their first primary cancer were excluded from the study. Those who 
were diagnosed with either small- or large-cell carcinomas were excluded from the study 
(n=19,261).  
Eleven patients who changed their residence, moving from Appalachian to Non-
Appalachian region or vice versa, after their first diagnoses, were also excluded from the study 
population.  
In addition, 631 patients who did not develop a subsequent primary cancer after being 
diagnosed with lung cancer as their first primary, but who were initially marked as those having 
two or more primaries, were excluded from the final sample. There was a high probability that 
those subjects were either mistakenly coded as having multiple primaries, or those patients were 
diagnosed with multiple primaries simultaneously to their lung cancer diagnosis, which did not 
satisfy the previously mentioned criteria of not developing a subsequent primary cancer within 3 
months period.  
2.4.  Final Study Sample. 
 As mentioned in the section 2.2., 46,708 (2,328 who developed a subsequent primary 
cancer and 44,380 who did not) were initially identified from the existing datasets. However, 
20,254 subjects were excluded, as described in section 2.3. Therefore, the final sample contained 
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26,456 subjects, 1,438 of whom had multiple primary cancers, and 25,018 had single primary 
lung cancers. 
2.5.  Data Collection and Measures. Subject Recruitment Methods.   
Secondary data, including information on patient age, gender, race, histology and 
morphology of cancer, stage at diagnosis, and received treatment, was obtained from the SEER 
database. The data was limited to Kentucky cancer cases only.  
This study was approved by the Institutional Review Board of the University of 
Kentucky (#16-0210-X1B) and received Exemption Certification for Protocol No. 16-0210-X1B. 
2.6.  Potential Risks for Study Subjects. 
It should be mentioned here that the research involved no more than minimal risk as 
subjects were not recruited for this study. Patient information was earlier reported to SEER. All 
data used for analysis was de-identified.  
 2.7.  Confidentiality. 
Since SEER database does not include any personal identifier, i.e. patient name, social 
security number, personal addresses, no patients were identified. Moreover, no attempts will be 
made, neither in the way of potential publications nor in presentations of the results of the study, to 
use the data to identify those patients. 
2.8.  Data Analysis. 
Statistical analyses were carried out using SAS version 9.4.  
Exploratory analyses included the use of descriptive statistics. Specifically, means, 
standard deviations, quartiles, and ranges were examined for continuous variables, and 
frequencies and percentages were examined for categorical variables. Results were examined by 
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main exposure (Appalachia versus Non-Appalachia Kentucky), which was of primary interest in 
this study. Therefore, descriptive statistics are presented by exposure groups in Table 1. 
In addition, for categorical variables, Pearson χ2 and Fisher’s Exact Tests (if the expected 
cell was ≤5) were used to determine if the associations were statistically significant. The 
Wilcoxon-Mann-Whitney test was used for continuous variables to determine differences 
between two exposed groups. Two-sided p-values ≤.05 were considered statistically significant. 
The Wilcoxon-Mann-Whitney test was used to determine if two groups were different 
with regards to age, survival time, and time during which a subject could develop an event of 
interest. The Wilcoxon-Mann-Whitney test was carried out, since those three continuous 
variables failed the normality tests (Kolmohorov-Smirnov test: Page<.01, Psurvival<.01, and 
Shapiro-Wilk: Ptimetoevent<.0001). 
There were significant differences between lung cancer patients residing in Appalachia 
Kentucky compared to those residing in the Non-Appalachian region with respect to the number 
of primary cancers they developed during their lifetime as shown in Table 1. It should be 
emphasized here that the purpose of this research was to assess if there were differences between 
Appalachian and Non-Appalachian populations regarding development of subsequent primary 
cancers in lung cancer patients. Therefore, the aim was to assess differences among those who 
developed multiple primary cancers (regardless of the number of those primary cancers) 
compared to those who did not. Table 2 presented descriptive statistics for patients in each of the 
two outcome groups: those with multiple primaries against those with single primaries. Similarly 
to Table 1, Pearson χ2 and Fisher’s Exact Tests (if the expected cell was ≤5) were used to 
determine whether the associations for categorical variables were statistically significant. The 
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Wilcoxon-Mann-Whitney test was used for continuous variables to determine differences in two 
outcome groups. Two-sided p-values ≤.05 were considered statistically significant. 
The next step was to assess the unadjusted associations for independent covariates and 
the outcome – development of multiple primary cancer. Therefore, univariate analysis using Cox 
proportional hazards models was carried out, with: 
• development of multiple primary lung cancers as the “censor” variable; 
• the “time” variable was calculated as observed survival from the time of the lung 
cancer diagnosis for those who did not develop another primary cancer until death or the end of 
the study period; and the difference in observed survival between 1st and 2nd diagnoses for those 
who developed another primary cancer. 
The univariate and multivariable Cox proportional hazards models were used to control 
for the time from diagnosis to death or a second primary cancer (the differences were considered 
statistically significant for p-values of <0.05).  
 According to Table 3, which presents the results of univariate models, the main exposure 
covariate – residing in Appalachian region – was not statistically significantly associated with 
the outcome. Race, unknown status for patients’ tumor stage, receiving radiotherapy treatment, 
surgery, and adenocarcinoma diagnosis were also not found to be significant. All other 
associations were statistically significant. As a result, the next step was to carry out a 
multivariable Cox proportional hazards regression in order to estimate adjusted hazard ratios of 
developing subsequent primary cancers, as well as to examine the factors associated with 
development of a second cancer. 
It was decided to fit a multivariable Cox proportional hazards model with all of the 
assessed covariates with the exception of race. The association of race with the outcome was not 
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significant, the number of blacks with multiple primaries was small (59 cases) and there was no 
particular research interest to observe differences between patients of different races.  
Backward elimination with a significance level of five percent was carried out for the 
first multivariable model, starting with the main effects and interactions for all the 
aforementioned potential predictors. Therefore, the first multivariable Cox proportional hazards 
model included the following covariates: Appalachian region, Age at diagnosis, Histologic Type 
ICD-O-3, Grade, Tumor Stage, Gender, Radiotherapy, and Surgical procedure. The regression 
revealed that there were no statistically significant associations between the outcome and 
Appalachian region, Histologic Type ICD-O-3, and Radiotherapy1. Since residence in the 
Appalachian region was the main exposure and receiving radiotherapy as a treatment for the 
initial lung cancer was of a great research interest, only Histologic Type ICD-O-3 covariate was 
excluded. The second model was fit with the remaining two-way interactions.  
As for model fit statistics, the second model (without Histologic Type ICD-O-3 
covariate) had a lower AIC comparing to the first model: AIC1=17486.26, SBC1=17555.837, 
AIC2=17484.67, SBC2=17544.308. Therefore, the second model was considered the final one. 
In addition, to explain the study sample better, unadjusted Kaplan-Meier estimated 
survival curves and corresponding log-rank test results are presented in the Appendix for those 
covariates which were significant in the final model. Included are comparisons of (1) patients 
residing in Appalachian versus Non-Appalachian regions, (2) two gender groups, (3) patients 
diagnosed with lung cancer on a different stage and (4) with a different grade of tumor, (5) 
patients who had or had not had their surgery performed. The Kaplan-Meier estimated survival 
                                                 
1 Appendix. Model 1  
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curves were used to visually show differences in survival between comparison groups, and the 
log-rank test was used to determine statistical significance with respect to the population survival 
curves.  
2.9.  Independent and Dependent Variables.  
Variable 1 - Appalachia Region – patients were divided in two geographical regions: 
Appalachia and non-Appalachia Kentucky, depending on their official residence at the time of the 
diagnosis of their lung cancer [50]. 
Variable 2 – Age at Diagnosis (measured in years) – defines the age of the patient when 
they were diagnosed with lung cancer [50]. 
Variable 3 – Gender – patients were divided into female or male gender groups [50]. 
Variable 4 – Race – patients were divided into three groups: Blacks, Whites, and Other, 
which includes American Indian/AK Native, Asian/Pacific Islander, and also those with no 
information provided [50]. 
Variable 5 – Vital status – defines the patients’ status on December 31, 2013 as the study 
cutoff date [50]. The variable was only used to determine survival times and in the descriptive 
analysis. 
Variable 6 – Number of Survival Months after Diagnosis of Lung Cancer – defines 
observed survival time measured in months [50].  
Variable 7 – Time to Event (development of a subsequent primary cancer) – defines 
observed time, measured in months, from data of diagnosis to the diagnosis of a second primary 
or death.  
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Variable 8 – Number of Primaries – defines the total number of tumors for a person 
developed during their lifetime [50]. The variable was used for exploratory purposes only and in 
the descriptive analysis. 
Variable 9 – Histologic Type ICD-O-3 – the records of tumor histology coded according 
to ICD-O-3 values [50, 51]. For this research project, only non-small (adenocarcinomas and 
squamous) cell carcinomas were included.  
Variable 10 – Summary Stage 2000 (1998+) was derived from Collaborative Stage (CS) 
for 2004+ and extent of disease (EOD) from 1998-2003 [50]. The following were the values: in 
situ, localized, regional, distant, and unknown. 
Variable 11 – Grade – defines grade of the tumor based on grade codes in ICD-O-3. (Cases 
diagnosed in 1973-2000 were coded in earlier versions and may lack the specificity of the 2001+ 
cases that were coded directly) [50]. The following were the values: grade I and II, grade III and 
IV, unknown (patients’ status was either unknown or tumors could not been graded). 
Variable 12 – Radiation – Patients having radiation as a treatment for their initial lung 
cancer [50]. The following were the values: yes, no, unknown (status is unknown, or patients 
refused to receive the treatment). 
Variable 13 – Surgical procedure – Patients having surgery as a treatment for their lung 
cancer [50]. The following were the values: yes, no, unknown (status is unknown, or patients 
refused to go through a surgical procedure). 
Variable 14 – Multiple Primary – the outcome binary variable that divided the study 
subjects in two groups: those who developed multiple primaries (“1”), and those who had a single 
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primary lung cancer (“0”). This variable was used as the “censor” variable for the Cox proportional 
hazards Regression. 
Variable 15 – Time - observed survival from the time of the lung cancer diagnosis for those 
who did not develop another primary cancer, and the difference in observed survival between 1st 
and 2nd diagnoses for those who developed another primary cancer. 
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III. RESULTS  
3.1. Univariate Descriptive Statistics and Bivariate Findings with Respect to the 
Exposed and Unexposed Groups. Characteristics of the Study Sample. 
In Table 1, basic information on descriptive statistics for lung cancer patients in the 
exposed and unexposed groups is presented. Means and standard deviations are provided for 
continuous variables, whereas frequencies and column percentages are provided for categorical 
variables. For categorical variables, Pearson χ2 and Fisher’s Exact Tests (if the expected cell was 
≤5) were used to determine if the association between exposure and the outcome was statistically 
significant, while the Wilcoxon-Mann-Whitney test was used for continuous variables. Two-
sided p-values ≤.05 were considered statistically significant. 
Based on the descriptive statistics from the Table 1 and the results of the Wilcoxon-
Mann-Whitney test, the time to development of subsequent cancers was approximately equally 
distributed in both Appalachian and Non-Appalachian populations (p=0.7147), whereas these 
two exposure groups were statistically significantly different from each other with respect to 
distribution of other assessed factors. These include age at diagnosis (p <0.0001), gender 
(p<0.0001), race (p<0.0001), histology (p<0.0001), tumor stage (p<0.0001), grade (p=0.0002), 
received treatment of lung cancer, including radiotherapy (p<0.0001) and surgery (p<0.0001), 
number of months survived after the diagnosis of the lung cancer (p <0.0001), and the number of 
alive people (p=0.0014).  
According to the results presented in Table 1, lung cancer patients who were residents of 
the Appalachian region, on average, were diagnosed at an earlier age compared to patients from 
the Non-Appalachian region (65.39 vs. 66.78 years old). Appalachians had more prolonged 
median survival time from the date of the lung cancer diagnosis (35 vs. 8 months), albeit the 
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average survival time for patients from Appalachian region was shorter (17.29 vs. 19.37 
months). Overall, the Appalachian population had a smaller percentage of those who were still 
alive at the end of the study period (17.83% vs. 19.48%).  
As compared to Non-Appalachians, patients residing in the Appalachian region had a 
slightly shorter average time to develop subsequent cancers (30.79 vs. 31.13 months). However, 
this difference was not statistically significant (p=0.7147).  
The percentage of men diagnosed with lung cancer among the Appalachian population 
was higher (62.73% vs. 57.08%), and fewer female subjects were diagnosed with lung cancer 
when comparing Appalachian and Non-Appalachian populations (37.27% vs. 42.92%).  
There were fewer blacks or patients of other races (American Indian/AK Native, 
Asian/Pacific Islanders) among the Appalachian population (1.29% vs. 8.82%, 0.12% vs. 0.47%, 
respectively), whereas there were more whites in the Appalachian population compared to the 
Non-Appalachian population (98.59% vs. 90.71%).  
The Appalachian population had a smaller percentage of those with adenocarcinomas 
(37.08% vs. 44.69%), but larger percentages of those diagnosed and coded as having non-small 
and squamous cell carcinomas (25.07% vs. 20.75%, 37.85% vs. 34.56%, respectively).  
There were smaller percentages of patients who were residents of the Appalachian 
region, diagnosed with stage II and IV tumors (17.69% vs. 18.51%, 50.28% vs. 51.34%, 
respectively), albeit the Appalachian population was characterized with a larger percentages of 
patients with stage III and those with unknown stage tumors (27.17% vs. 26.69%, 4.86% vs. 
3.47%). No lung cancer patient had a stage I tumor.  
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There were fewer patients residing in the Appalachian region that had tumors of grade I 
and II, as well as those whose tumor grade was either unknown or impossible to be defined 
(21.31% vs. 23%, 44.34% vs. 44.9%, respectively); whereas there was a larger percentage of the 
Appalachian population who had grade III and IV tumors (34.35% vs. 32.1%).  
Similar trends could also be observed for two treatment variables: radiotherapy and 
surgical procedure. Appalachian lung cancer residents received radiotherapy and had surgery 
performed more often (46.62% vs. 45.07%, 67.27% vs. 64.03%, for radiotherapy and surgery 
respectively), albeit more Appalachians either refused the prescribed treatment or did not survive 
long enough to receive the treatment (12.55% vs. 9.02%, 7.01% vs. 4.09%).  
In addition, there were slight, yet statistically significant, differences between 
Appalachian and Non-Appalachian patients regarding the overall number of primary cancers 
they developed during their lifetime (p=0.0422). Appalachians had higher percentages of those 
who had only lung cancer (96.38% vs. 95.79%) and those who had 3 primaries, i.e., those who 
developed two more primary cancers beside lung cancer (0.45% vs. 0.41%). On the other hand, 
Non-Appalachians had slightly higher percentages of those who developed one (3.74% vs. 
3.15%) and three primaries after being diagnosed with lung cancer (0.07% vs. 0.02%).  
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Table 1. Descriptive statistics for patients in exposed and unexposed groups. Means and 
standard deviations (in parentheses) are provided for continuous variables, whereas frequencies 
and column percentages (in parentheses) are provided for categorical variables. The two-sided p-
values ≤.05 for Pearson χ2 and Fisher’s Exact, and the Wilcoxon-Mann-Whitney tests were 
considered statistically significant (N=26456).  
 
 
Variable 
 
Appalachia 
(8536, 32.26%) 
 
Non-Appalachia 
(17920, 67.74%) 
 
P-value 
Age at diagnosis (years)    
n 8536 17920  
 
<.0001**** 
Mean (SD) 65.39 (10.41) 66.78 (10.87) 
Median (Q1, Q3) 66 (58, 73) 67 (59, 75) 
(Min, Max) (30, 100) (21, 99) 
# Survival months after 
diagnosis of Lung Cancer 
   
n 8528 17892  
 
<.0001**** 
Mean (SD) 17.29 (25.51) 19.37 (27.74) 
Median (Q1, Q3) 35 (17, 57) 8 (2,23) 
(Min, Max) (4, 136) (0, 155) 
Time to Event (months) 
(development of a 
subsequent primary 
cancer) 
   
n,  309 (3.62) 755 (4.21)  
 
0.7147ns 
Mean (SD) 41.65 (30.79) 41.06 (31.13) 
Median (Q1, Q3) 35 (17, 57) 34 (16, 59) 
(Min, Max) (4, 136) (4, 154) 
 
 
Variable 
 
Appalachia 
(8536, 32.26%) 
 
Non-Appalachia 
(17920, 67.74%) 
 
P-value 
Gender    
n 8536 17920  
<.0001****2 Female n, (%) 3181 (37.27) 7691 (42.92) 
Male n, (%) 5355 (62.73) 10229 (57.08) 
Race    
n 8536 17920  
 
<.0001**** 
Black 110 (1.29) 1580 (8.82) 
White 8416 (98.59) 16256 (90.71) 
Other (American Indian/AK 
Native, Asian/Pacific Islander) 
10 (0.12) 84 (0.47) 
                                                 
2 Fisher’s Exact Test 
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Vital Status    
n 8536 17920  
.0014***3 Alive n, (%) 1522 (17.83) 3491 (19.48) 
Dead n, (%) 7014 (82.17) 14429 (80.52) 
# Number of Primaries    
n 8536 17920  
0.0422* Lung cancer only n, (%) 8227 (96.38) 17165 (95.79) 
LC plus another cancer 
n, (%) 
269 (3.15) 670 (3.74) 
LC plus 2 more cancers 
n, (%) 
38 (0.45) 73 (0.41) 
LC plus 3 more cancers 
n, (%) 
2 (0.02) 12 (0.07) 
Histologic Type ICD-O-3    
n 8536 17920  
<.0001**** Adenocarcinoma n, (%) 3165 (37.08) 8008 (44.69) 
Non-small (NOS) n, (%) 2140 (25.07) 3719 (20.75) 
Squamous n, (%) 
 
3231 (37.85) 6193 (34.56) 
Stage    
n 8536 (32.26) 17920 (67.74)  
 
<.0001**** 
In situ n, (%) 0 (0.00) 0 (0.00) 
Localized n, (%) 1510 (17.69) 3317 (18.51) 
Regional n, (%) 2319 (27.17) 4782 (26.69) 
Distant n, (%) 4292 (50.28) 9200 (51.34) 
Unstaged/Unknown n, (%) 415 (4.86) 621 (3.47) 
Grade    
n 8536 17920  
0.0002*** Grade I and II n, (%) 1819 (21.31) 4121 (23.00) 
Grade III and IV n, (%) 2932 (34.35) 5753 (32.10) 
Unknown n, (%) 3785 (44.34) 8046 (44.90) 
Radiation    
n 8536 17920  
<.0001**** Yes n, (%) 3618 (42.39) 7949 (44.36) 
No n, (%) 3847 (45.07) 8354 (46.62) 
Unknown n, (%) 1071 (12.55) 1617 (9.02) 
Surgical procedure    
n 8536 17920  
<.0001**** Yes n, (%) 2472 (28.96) 5132 (28.64) 
No n, (%) 5466 (64.03) 12055 (67.27) 
Unknown n, (%) 598 (7.01) 733 (4.09) 
 
                                                 
3 Fisher’s Exact Test 
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3.2. Univariate Descriptive Statistics and Bivariate Findings with Respect to the 
Outcome Groups.  
In Table 2, basic information on descriptive statistics for patients in each of the two 
outcome groups is presented. Means and standard deviations are provided for continuous 
variables, whereas frequencies and row percentages are provided for categorical variables. For 
categorical variables, Pearson χ2 and Fisher’s Exact Tests (if the expected cell was ≤5) were used 
to determine if the association between exposure and the outcome was statistically significant, 
while the Wilcoxon-Mann-Whitney test was used for continuous variables. Two-sided p-values 
≤.05 were considered statistically significant. 
As shown in Table 2, the two outcome groups were significantly different with respect to 
the following factors: age at diagnosis (p=0.0005), number of months survived after the 
diagnosis of lung cancer (p<0.0001), place of residence (p=0.0228), histology (p<0.0001), tumor 
stage (p<0.0001), grade (p<0.0001), received treatment of lung cancer, including radiotherapy 
(p<0.0001) and surgery (p<0.0001).  
A slightly larger percentage of female lung cancer patients developed multiple primaries 
(4.29% vs. 3.84%), while a little larger percentage of white subjects developed multiple 
primaries (4.07%), followed by black patients (3.49%), and those of other racial background 
(1.06%). Hence, no statistically significant differences were observed regarding patients’ gender 
(p=0.0699) and race (p=0.1661).  
Those who developed subsequent primary cancers after having been diagnosed with lung 
cancer, were on average one year younger (65.44 vs. 66.37 years old). Patients who developed 
multiple primaries had a much longer average and median survival time after the date of 
diagnosis for the initial lung cancer (67.73 vs. 16.81 months, 59 vs. 7 months, respectively).  
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More patients residing in the Non-Appalachian region developed multiple primaries as 
compared to Appalachian patients (4.21% vs. 3.62).  
Approximately the same percentages of patients developed multiple primary cancers 
among those who had squamous and adenocarcinomas (4.73%, 4.48%, respectively); however, 
only two percent of patients with records of non-small cell carcinomas developed multiple 
primaries. 
Comparing lung cancer patients with different tumor stages, we can observe that a larger 
percentage of people with stage II tumors developed subsequent primary cancers (10.46%), 
followed by subjects with stage III tumors (5.76%), those whose tumor stage was unknown 
(3.96), and those with stage IV tumors (0.81%).  
Similarly, there were more patients with multiple primary cancers who were diagnosed 
with grade I and II tumors in the lung (8.01%), followed by those with grade III and IV tumors 
(4.58%), and 1.61% of patients with ungraded tumors. 
Approximately the same percentages of those subjects who did not receive radiotherapy 
as the treatment for the initial lung cancer (5.20%) and those whose status was unknown (5.13%) 
eventually developed multiple primaries. However, only roughly half (2.52%) of patients who 
received radiotherapy developed subsequent cancers. 
Conversely, among those patients who had gone through a surgical procedure as the 
treatment of the initial lung cancer, 10.89 percent developed multiple primary cancers, whereas 
among those who did not have surgery, only 1.21 percent developed subsequent primary cancers, 
similarly to the percentage of those who refused the surgery or whose status was unknown 
(1.8%).     
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Table 2. Descriptive statistics for patients in two outcome groups. Means and standard 
deviations (in parentheses) are provided for continuous variables, whereas frequencies and 
column percentages (in parentheses) are provided for categorical variables. The two-sided p-
values ≤.05 for Pearson χ2 and Fisher’s Exact, and the Wilcoxon-Mann-Whitney tests were 
considered statistically significant (N=26456).  
 
Variable Multiple primaries  
N=1064 
Single primary 
N=25392 
P-value  
 
Age at diagnosis (years)    
N 1064 25392  
.0005*** Mean (SD) 65.44 (8.91) 66.37 (10.81) 
Median (Q1, Q3) 66 (59, 72) 67 (59, 74) 
(Min, Max) (38, 90) (21, 100) 
# Survival months after 1st 
diagnosis 
   
N 1064 25356  
 
<.0001**** 
 
Mean (SD) 63.73 (36.68) 16.81 (24.85) 
Median (Q1, Q3) 59 (32, 89) 7 (2, 20) 
(Min, Max) (4, 155) (0, 155) 
 
 
N  
Variable Multiple primaries  
N=1064 
Single primary 
N=25392 
P-value  
 
Appalachia region     
26456 n 1064 25392  
8536 Yes n, (row %) 309 (3.62) 8227 (96.38)  
0.0228*4 
 
17920 No n, (row %)  755 (4.21) 17165 (95.79) 
 Gender    
26456 n 1064 25392  
 
0.0699 ns5 
 
 
19872 Female n, (row %) 466 (4.29) 10406 (95.71) 
15584 Male n, (row %) 598 (3.84) 14986 (96.16) 
 Race    
26456 n 1064 25392  
 
0.1661 ns 
1690 Black n, (row %) 59 (3.49) 1631 (96.51) 
24672 White n, (row %) 1004 (4.07) 23668 (95.93) 
94 Other (American Indian/AK 
Native, Asian/Pacific 
Islander/Unknown) n, (row %) 
 
1 (1.06) 
 
93 (98.94) 
 Histologic Type ICD-O-3    
26456 n 1064 26356  
                                                 
4 Fisher’s Exact Test 
5 Fisher’s Exact Test 
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11173 Adenocarcinoma n, (row %) 501 (4.48) 10672 (95.52) <.0001***
* 5859 Non-small (NOS) n, (row %) 117 (2.00) 5742 (98.00) 
9424 Squamous n, (row %) 446 (4.73) 8978 (95.27) 
 Stage    
26456 n 1064 26356  
 
<.0001***
* 
0 In situ n, (row %) 0 (0.00) 0 (0.00) 
4827 Localized n, (row %) 505 (10.46) 4322 (89.54) 
7101 Regional n, (row %) 409 (5.76) 6692 (94.24) 
13492 Distant n, (row %) 109 (0.81) 13383 (99.19) 
1036 Unknown n, (row %) 41 (3.96) 995 (96.04) 
 Grade     
26456 n 1064 26356  
<.0001***
* 
5940 Grade I and II n, (row %) 476 (8.01) 5464 (91.99) 
8685 Grade III and IV n, (row %) 398 (4.58) 8287 (95.42) 
11831 Unknown n, (row %) 190 (1.61) 11641 (98.39) 
 Radiation     
26456 n 1064 26356  
<.0001***
* 
11567 Yes n, (row %) 291 (2.52) 11276 (97.48) 
12201 No n, (row %) 635 (5.20) 11566 (94.80) 
2688 Unknown n, (row %) 138 (5.13) 2550 (94.87) 
 Surgical procedure    
26456 n 1064 26356  
<.0001***
* 
7604 Yes n, (row %) 828 (10.89) 6776 (89.11) 
17521 No n, (row %) 212 (1.21) 17309 (98.79) 
1331 Unknown n, (row %) 24 (1.80) 1307 .
20) 
 
3.3.  Bivariate Findings.  
Table 3 presents the results from univariate analysis using Cox proportional hazards 
regression models, with development of multiple primary lung cancers as the “censor” variable, 
the “time” variable which expressed observed survival from the time of the lung cancer diagnosis 
for those who did not develop another primary cancer, and the difference in observed survival 
between 1st and 2nd diagnoses for those who developed another primary cancer. Univariate 
analysis allowed assessing unadjusted associations. 
The univariate Cox regression models did not reveal statistically significant association 
for the primary exposure – residing in Appalachian region (HR = 0.993, 95% CI: 0.869-1.133).  
33 
 
The model also did not demonstrate significant results for the race covariate. The 
observed results were the following: whites had 12.1 percent higher observed hazards to develop 
multiple primary cancers as compared to blacks (95% CI: 0.862-1.457), whereas patients of other 
nationalities had 67.3 percent smaller hazards comparing to blacks (95% CI: 0.046-2.348). 
 On the other hand, univariate Cox proportional hazards regressions revealed a number of 
other statistically significant associations. For instance, being diagnosed with lung cancer at a later 
age increased the hazards of development of a subsequent primary cancer by 1.5 percent per 
increase in one year (95% CI: 1.008-1.021).  
Males had 16.5 percent higher hazards to develop subsequent cancers as compared to 
female lung cancer patients (95% CI: 1.032-1.315).  
Furthermore, a statistically significant protective effect of being diagnosed with a non-
small lung carcinoma was observed, decreasing the hazards of developing a subsequent primary 
cancer by 31.8 percent (95% CI: 0.556-0.836). Patients who had adenocarcinomas had 21.4 
percent smaller hazards to develop another primary cancer as compared to squamous cell 
carcinomas. However, the former results did not have sufficient statistical significance (95% CI: 
0.780-1.007). 
A statistically non-significant association was observed for those with unknown status for 
radiotherapy (HR=0.84, 95% CI: 0.697-1.011). However, compared to those who did not receive 
radiation as the treatment for lung cancer, patients who had radiation had 18.9 percent smaller 
hazards to develop multiple primaries (95% CI: 0.705-0.933).  
Compared to those who did not have surgery as a treatment for the initial lung cancer, 
patients who had a surgical procedure performed had 1.7 times (95% CI: 1.452-1.991) higher 
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hazards to develop a subsequent cancer, whereas those with unknown status had 5.3 percent 
smaller hazards, albeit the association was non-significant (95% CI: 0.621-1.446).  
Patients who had grade III and IV tumors had 13.3 percent smaller hazards as compared 
to those with grade I and II tumors (95% CI: 0.759-0.991). Study subjects whose status was 
unknown or whose tumors were ungraded had 40.5 percent smaller hazards as compared to those 
with grade I and II tumors. (95% CI: 0.502-0.706).  
The following results also demonstrated that having a stage IV tumor decreased the 
hazards of the outcome by 48.6% comparing to the patients with stage II tumors ( 95% CI: 
0.415-0.636). Having stage III tumors also had an observed protective effect from developing 
multiple primary cancers, yet the results were not significant (HR=0.897, 95% CI: 0.787-1.022). 
Those patients whose status was unknown had 24.6 percent higher hazards to develop multiple 
primary cancers, albeit that association was not statistically significant either (95% CI: 0.548-
1.036). 
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Table 3. Univariate Cox proportional hazards models’ results, using development of 
multiple primary lung cancers as the “censor” variable, and the “time” variable which expressed 
observed survival from the time of the lung cancer diagnosis for those who did not develop 
another primary cancer, and the difference in observed survival between 1st and 2nd diagnoses for 
those who developed another primary cancer (N=26456).  
 
Variable HR 95% CI P-value 
Age at diagnosis (years) 1.014 1.008- 1.020 <0.0001 
Appalachia region 
No* 
Yes 
 
 
0.993 
 
 
0.869- 1.133 
 
 
0.9117 
Gender 
Female* 
Male 
 
 
1.165 
 
 
1.032-1.315 
 
 
0.0138 
Race 
Black* 
White 
Other 
 
 
1.121 
0.327 
 
 
0.862- 1.457 
0.046- 2.348 
 
 
0.3946 
0.2667 
Histologic Type ICD-O-3 
Squamous* 
Adenocarcinoma 
Non-Small (NOS) 
 
 
0.886 
0.682 
 
 
0.780- 1.007 
0.556- 0.836 
 
 
0.0642 
0.0002 
Radiotherapy 
No* 
Yes 
Unknown 
 
 
0.811 
0.840 
 
 
0.705-0.933 
0.697-1.011 
 
 
0.0035 
0.0651 
Surgical procedure 
No 
Yes* 
Unknown 
 
 
1.700 
0.947 
 
 
1.452-1.991 
0.621-1.446 
 
 
<0.0001 
0.8025 
Grade 
Grade I and II * 
Grade III and IV 
Unknown 
 
 
0.867 
0.595 
 
 
0.759-0.991 
0.502-0.706 
 
 
0.0365 
<0.0001 
Tumor Stage 
Localized* 
Regional 
Distant 
Unknown 
 
 
0.897 
0.514 
0.754 
 
 
0.787- 1.022 
0.415- 0.636 
0.548- 1.036 
 
 
0.1022 
<0.0001 
0.0819 
HR – hazard ratio, CI – confidence interval 
*reference group 
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3.4. Multivariable Findings.  
Table 4 presents results from the final Cox proportional hazards model, using 
development of multiple primary cancers as the “censor” variable, the “time” variable which 
expressed observed survival from the time of the lung cancer diagnosis for those who did not 
develop another primary cancer, and the difference in observed survival between 1st and 2nd 
diagnoses for those who developed another primary cancer (N=26456).  
The final model indicated that there were no statistically significant differences between 
Appalachian and Non-Appalachian populations with respect to the hazards of developing a 
subsequent primary cancer (HR: 1.002, 95% CI: 0.877-1.145).  
The adjusted analysis revealed that increasing age at diagnosis by one year was 
associated with increase in hazards of development of multiple primary cancer by 1.5 percent 
(95% CI:1.008-1.021).  
Males had 16.9 percent higher hazards to develop subsequent cancers compared to 
female lung cancer patients (95% CI: 1.035-1.320).  
Comparing to patients who had not had a surgery as a treatment of the initial lung cancer, 
to patients who had surgical procedure performed have shown a 1.446 times (95% CI: 1.183-
1.767) higher hazards to develop a subsequent cancer, whereas those with unknown status had 
8.6% smaller hazards, albeit the association was not significant (95% CI: 0.583-1.433).  
A statistically non-significant association was also observed for radiotherapy. As 
compared to those who did not receive radiation as their treatment for lung cancer, patients who 
had radiation therapy had 9.6 percent higher hazards of developing multiple primaries (95% CI: 
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0.932-1.290), and those with unknown status had 7.6 percent smaller hazards (95% CI: 0.764-
1.117). 
Patients who had grade III and IV tumors had 7.8 percent smaller hazards as compared to 
those with grade I and II tumors. However, the association was not statistically significant (95% 
CI: 0.805-1.056). Study subjects whose status was unknown or whose tumors were ungraded had 
23 percent smaller hazards as compared to those with grade I and II tumors (95% CI: 0.634-
0.937).  
The following results demonstrated that having a stage IV tumor decreased the hazards of 
the outcome by 31.6% comparing to the patients with stage II tumors (HR=0.684, 95% CI: 
0.540-0.865). Having stage III tumors also had an observed protective effect from developing 
multiple primary cancers, however, the results were not significant (HR= 0.942, 95% CI: 0.821-
1.082). Those patients whose status was unknown had 1.7 percent higher hazards of developing 
of multiple primary cancers, albeit that association was not statistically significant either (95% 
CI: 0.723-1.433). 
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Table 4. Multivariable Cox proportional hazards regression’s results for the final model 
of analysis of factors affecting development of multiple primary cancers as the “censor” variable, 
the “time” variable which expressed observed survival from the time of the lung cancer diagnosis 
for those who did not develop another primary cancer, and the difference in observed survival 
between 1st and 2nd diagnoses for those who developed another primary cancer (N=26456)  
 
Variable Adjusted HR 95% CI P-value 
Appalachia region 
No* 
Yes 
 
 
1.002 
 
 
0.877-1.145 
 
 
0.9713 
Age at diagnosis (years) 1.015 1.008-1.021 0.0001 
Gender 
Female* 
Male 
 
 
1.169 
 
 
1.035-1.320 
 
 
0.0120 
Surgical procedure 
No* 
Yes 
Unknown 
 
 
1.446 
.914 
 
 
1.183-1.767 
0.583-1.433 
 
 
0 .0003 
0.6965 
Radiotherapy 
No* 
Yes 
Unknown 
 
 
1.096 
0.924 
 
 
0.932-1.290 
0.764-1.117 
 
 
0.2677 
0.4142 
Grade 
Grade I and II * 
Grade III and IV 
Unknown 
 
 
0.922 
0.770 
 
 
0.805-1.056 
0.634-0.937 
 
 
0.2423 
0.0089 
Tumor Stage 
Localized* 
Regional 
Distant 
Unknown 
 
 
0.942 
0.684 
1.017 
 
 
0.821-1.082 
0.540-0.865 
0.723-1.433 
 
 
0.4004 
0.0015 
0.9210 
HR – hazard ratio, CI – confidence interval 
*reference group 
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IV. DISCUSSION 
4.1.  Interpretation of the Results. Consistency with Previous Studies. 
The aim of this study was to examine whether there were differences in the development 
of subsequent primary cancers in lung cancer patients residing in the Appalachian versus Non-
Appalachian regions of Kentucky. Interestingly, based on the descriptive statistics and bivariate 
results presented in Table 1, Appalachian and Non-Appalachian lung cancer patients were 
different with respect to a number of factors. Namely, these include age at diagnosis of lung 
cancer, survival months, gender, race, histology, stage and grade of tumors, and received 
treatment (radiation and surgery). Appalachian and Non-Appalachian residents were 
significantly different even based on the number of primary cancers which a patient could 
develop during the lifetime. 
However, these two exposure groups did not differ significantly with respect to the 
observed mean and median time of development of a subsequent primary cancer. Thus, both 
univariate and multivariable hazards models did not reveal any differences between Appalachian 
and Non-Appalachian lung cancer patients with respect to the outcome. It was concluded that, 
even though the variable “Number of Primary Cancers” was treated as a categorical one, 
statistical significance of a Pearson χ2 presented in Table 1, could be still explained by a large 
sample size, and thus, the power of the test.  
Overall, the multivariable proportional hazards model revealed the results that were 
consistent with previous research, or that could be intuitively derived based on descriptive and 
bivariate findings. For instance, it was expected to see that patient diagnosed at older age would 
have higher hazards of developing another primary cancer, as typically the increase in incidence 
rates of many cancers is associated with increase in age [7].  
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In addition, other research showed that a more aggressive invasive treatment increased 
the overall survival for patients with multiple lung cancers [25, 28]. That is why we assumed that 
surgery was very likely to be associated with getting a second primary, as patients who had 
surgery were likely to live longer, and thus had a greater opportunity to develop a second 
primary. In contrast, patients who were diagnosed with stage IV lung cancer had very short 
survival times and were, thus, less likely to develop a second primary cancer. Moreover, those 
patients with unknown grade status also had smaller hazards of developing another primary 
cancer. This could be explained by the fact that in a number of patients it was impossible to 
differentiate and define the grade since they had stage IV tumors, the factor due to which their 
overall survival time could have been shortened. 
Radiation was expected to be a statistically significant factor, which should increase the 
hazards of development of second primary cancers. Performing radiation indeed increased the 
hazards; however, this association was not significant, even though the investigators did not 
distinguish different types or doses of radiation that patients received, but had rather defined 
three main groups (radiation performed, not performed, or unknown) in order not to lose power 
on every additional level.  
The results of this study were consistent with previous analysis based on SEER database, 
which showed that four percent of the patients who had the first primary cancer of the lung or 
other respiratory organs developed subsequent primary cancers. The median age at diagnosis of 
lung or other respiratory organs’ cancers was 67 years among those patients who developed 
multiple primary cancers [7]. This study has also revealed that relatively small percentage 
(4.94%) of lung cancer patients developed subsequent tumor events, and that the median age at 
diagnosis of patients who developed multiple primary cancers was 67 years. In addition, 
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consistent with previous studies [7, 41], the results of this study demonstrated that patients had to 
live long enough to develop subsequent primary cancers. According to Table 2, the mean 
observed survival time, measured in months, of those who had developed multiple primary 
cancers was almost four times longer than of those who had single primary lung cancers. 
Moreover, median survival time was more than eight times longer for the outcome group. Thus, 
if lung cancer was detected at an earlier stage and treatment could have been prescribed to the 
patients, thereby increasing their overall survival, it also increased the hazards to develop a 
second primary cancer. Therefore, very careful attention should be paid to lung cancer patients 
who demonstrate long overall survival, and especially those who undergo invasive treatment. 
Additional screening tests should be required to control the condition of this population of lung 
cancer patients.  
Previous studies have shown that female lung cancer patients, especially those with stage 
II tumors, had better survival compared to men [7]. Some studies explained this phenomenon by 
the fact that surgical procedures were performed on women with stage II tumors more frequently 
[7, 42]. Another possible explanation is that women are more likely to develop adenocarcinomas 
compared to men [7, 52], as Fu et al. showed that patients with any histologic type of stage II 
tumors other than adenocarcinomas had lower survival rates [42]. In addition, there could be a 
healthy screening effect as lung cancer could be detected on earlier stages among women who 
undergo their annual mammograms. Unexpectedly, the results of this study demonstrated that 
men had almost a 17 percent higher hazards of developing subsequent cancers compared to 
female subjects. A possible explanation is the inability to control for smoking in this analysis as 
because smoking is a major risk factor for many cancers, lung cancer in particular, and also for 
development of a second primary cancer [6, 7]. In addition, it is well known that the male 
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population of Kentucky has a higher prevalence of smoking [53, 54] compared to women. 
Therefore, further research is recommended to examine the influence of smoking as a potential 
confounding factor. 
4.2.  Strengths and Limitations of the Study. 
It should be emphasized that, besides examining whether there were differences in the 
development of subsequent primary cancers in lung cancer patients residing in the Appalachian 
versus Non-Appalachian regions of Kentucky, this study also identified other factors associated 
with the development of another primary cancer in lung cancer patients. Namely, age at 
diagnosis, gender, race, stage and grade of the tumor, and treatment (radiation or surgery). The 
final Cox proportional hazards model included all covariates that were considered as potential 
confounders. 
Because a prospective cohort study due to lack of individual-based information, the 
chosen design of a retrospective, population-based cohort study was the best option. A case-
control study design would not be appropriate here, as it would have required a defined cutoff 
time during which a patient could have developed a subsequent primary cancer, since it would 
have been critical for investigators to identify “cases” and “controls” correctly. This, in turn, 
would automatically reduce the sample size, and decrease the power.  
The Cox proportional hazards model, which allowed for controlling for the time from 
diagnosis to death or a subsequent primary cancer was the appropriate model. Adjusted logistic 
regression would not have allowed for controlling for the time from diagnosis to death or a 
subsequent primary cancer as well as for considering censoring cases of death due to various 
causes. 
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On the other hand, this study had a number of limitations. Firstly, it lacks 
generalizability. Kentucky lung cancer patients were considered the target population; thus, the 
results can be applied only to the population of Kentucky lung cancer patients. 
Another limitation of this study was that a large volume of missing data was included in 
order not to lose power in case subjects with missing values for important covariates had been 
excluded. Further research is recommended to examine how the estimates might change if 
missing cases were excluded or if the information could be obtained by linking SEER data to 
other databases (e.g., Medicaid or Medicare).  
Unfortunately, there was no individual-level information about smoking status of the 
patients. The investigators did not distinguish the types of subsequent primary cancers. Some of 
those could have been subsequent primary lung cancers. Studies exploring predictors of 
synchronous multiple lung cancers demonstrated that smoking (which is more prevalent among 
males) is a substantial risk factor [6, 7, 27]. Further research is recommended to examine the 
influence of smoking as a potential confounding factor. 
Moreover, the impact of comorbidities could not be assessed in this study. The SEER 
database includes variable that defines causes of death; however, the investigators could not use 
it since a large number of subjects were still alive at the time of defined cutoff. Further research 
is recommended to address this question.  
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V. SUMMARY, CONCLUSIONS, RECOMMENDATIONS 
This was a retrospective, population-based cohort study of Kentucky patients diagnosed 
with primary lung cancer between 2000 and 2013. The study population was drawn from the 
Kentucky Cancer Registry. Subjects were followed to determine if they developed subsequent 
primary cancers. The Cox proportional hazards model was used to control for the time from 
diagnosis to death or a second primary cancer. 
Even though unadjusted associations revealed some differences between Appalachian 
and Non-Appalachian populations of Kentucky lung cancer patients, the adjusted multivariable 
Cox proportional hazards regression analysis indicated that there were no differences between 
Appalachian and Non-Appalachian lung cancer patients with regards to development of 
subsequent primary cancers.  
Increasing age at diagnosis, as well as male gender and surgical treatment, increased the 
hazards of developing subsequent cancers, whereas having stage IV or ungraded tumors 
decreased the hazards of the developing subsequent primary cancers. 
The results of this study suggest that a number of improvements in Kentucky’s healthcare 
system with regards to prevention of multiple primary cancers in lung cancer patients can be 
considered. For instance, clinical surveillance, including early detection of lung cancer, 
screening of the male population and smokers, making careful and thoughtful choice of 
treatment, i.e. choosing between radiotherapy and surgery, and also assessment of long-term 
treatment effects. 
Further research is recommended to define whether the following factors could have 
made a difference to the adjusted estimates: educational attainment, poverty level, employment, 
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smoking status, number and sequence of treatments (i.e. radiotherapy and surgery), 
comorbidities, and occupational exposures.   
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APPENDIX 
  
Table 1. Model 1: All covariates except Race. 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Appalachia_Region__
A 
Appalachia 1 -0.0002094 0.06800 0.0000 0.9975 1.000 0.875 1.142 
Age_at_diagnosis1  1 0.01405 0.00320 19.2435 <.0001 1.014 1.008 1.021 
Histology1 Adenocarcinoma 1 -0.07646 0.06725 1.2924 0.2556 0.926 0.812 1.057 
Histology1 Non–small cell 
carcinoma 
1 -0.14585 0.10869 1.8005 0.1797 0.864 0.698 1.069 
GradeFirst Grade III and IV 1 -0.07528 0.07069 1.1340 0.2869 0.927 0.807 1.065 
GradeFirst Unknown 1 -0.24055 0.10164 5.6017 0.0179 0.786 0.644 0.959 
Summary_stage_2000_
_ 
Distant 1 -0.37506 0.12014 9.7461 0.0018 0.687 0.543 0.870 
Summary_stage_2000_
_ 
Regional 1 -0.06356 0.07065 0.8095 0.3683 0.938 0.817 1.078 
Summary_stage_2000_
_ 
Unstaged/Unknown 1 0.01644 0.17472 0.0089 0.9250 1.017 0.722 1.432 
Sex1 Male 1 0.14592 0.06291 5.3805 0.0204 1.157 1.023 1.309 
Radiotherapy1 Radiation performed 1 0.08765 0.08306 1.1136 0.2913 1.092 0.928 1.285 
Radiotherapy1 Unknown 1 -0.08356 0.09718 0.7394 0.3899 0.920 0.760 1.113 
Surgery1 Surgical procedure 
performed 
1 0.36172 0.10322 12.2795 0.0005 1.436 1.173 1.758 
Surgery1 Unknown 1 -0.09118 0.22946 0.1579 0.6911 0.913 0.582 1.431 
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Stratification by YEAR of DIAGNOSIS 
Table 2. Group 2000-2006, Model 2. 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Appalachia_Region__
A 
Appalachia 1 0.03624 0.08223 0.1942 0.6594 1.037 0.883 1.218 
Age_at_diagnosis1  1 0.01377 0.00388 12.6265 0.0004 1.014 1.006 1.022 
GradeFirst Grade III and IV 1 -0.04737 0.08206 0.3332 0.5638 0.954 0.812 1.120 
GradeFirst Unknown 1 -0.45484 0.12636 12.9561 0.0003 0.635 0.495 0.813 
Summary_stage_2000_
_ 
Distant 1 -0.28608 0.15756 3.2970 0.0694 0.751 0.552 1.023 
Summary_stage_2000_
_ 
Regional 1 -0.03754 0.08577 0.1916 0.6616 0.963 0.814 1.139 
Summary_stage_2000_
_ 
Unstaged/Unknown 1 0.14588 0.18514 0.6209 0.4307 1.157 0.805 1.663 
Sex1 Male 1 0.09888 0.07509 1.7340 0.1879 1.104 0.953 1.279 
Radiotherapy1 Radiation performed 1 -0.04066 0.10448 0.1515 0.6971 0.960 0.782 1.178 
Radiotherapy1 Unknown 1 -0.04087 0.10441 0.1532 0.6955 0.960 0.782 1.178 
Surgery1 Surgical procedure 
performed 
1 0.34516 0.13183 6.8546 0.0088 1.412 1.091 1.829 
Surgery1 Unknown 1 0.00286 0.25633 0.0001 0.9911 1.003 0.607 1.657 
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Table 3. Group 2007-2013, Model 2. 
Analysis of Maximum Likelihood Estimates 
Parameter  DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Appalachia_Region__
A 
Appalachia 1 -0.08837 0.12093 0.5341 0.4649 0.915 0.722 1.160 
Age_at_diagnosis1  1 0.01611 0.00557 8.3570 0.0038 1.016 1.005 1.027 
GradeFirst Grade III and IV 1 -0.13513 0.13078 1.0677 0.3015 0.874 0.676 1.129 
GradeFirst Unknown 1 0.12842 0.17426 0.5431 0.4611 1.137 0.808 1.600 
Summary_stage_2000_
_ 
Distant 1 -0.51394 0.18722 7.5356 0.0060 0.598 0.414 0.863 
Summary_stage_2000_
_ 
Regional 1 -0.08307 0.12476 0.4433 0.5055 0.920 0.721 1.175 
Summary_stage_2000_
_ 
Unstaged/Unknown 1 -0.79842 0.71965 1.2309 0.2672 0.450 0.110 1.844 
Sex1 Male 1 0.29771 0.11123 7.1636 0.0074 1.347 1.083 1.675 
Radiotherapy1 Radiation performed 1 0.32725 0.14193 5.3161 0.0211 1.387 1.050 1.832 
Radiotherapy1 Unknown 1 -0.36979 0.31602 1.3692 0.2419 0.691 0.372 1.284 
Surgery1 Surgical procedure 
performed 
1 0.57430 0.17415 10.8749 0.0010 1.776 1.262 2.498 
Surgery1 Unknown 1 -0.44879 0.59688 0.5653 0.4521 0.638 0.198 2.057 
 
  
52 
 
Figure 1. K-M Curve: There are no statistically significant differences between the 
exposed and unexposed groups not controlling for confounders 
 
Test of Equality over Strata        
  
Test    Chi-Square  DF  Pr > 
Chi-Square Log-Rank 0.0124  1  0.9115 
 Wilcoxon   0.6657  1  0.4146 
 -2Log(LR)   0.4567  1  0.4992 
 
 
According to the Figure 1, the log-rank tests revealed that there were no statistically 
significant differences between Appalachian and Non-Appalachian populations with respect to 
the probability of developing subsequent primary cancers over 155 months (59.44% vs. 56.5%, 
respectively; log-rank test: χ2=0.0124, p=.9115).  
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The study cohort included patients who were diagnosed from January 1, 2000 through 
December 31, 2013. Assuming that the medical care capabilities, including detection, 
diagnosing, and treatment of lung cancer might have changed over the thirteen-year time period, 
the investigators made an attempt of stratification based on the years of diagnosis of the initial 
lung cancer. Subjects were divided into two subgroups: those who were diagnosed between 2000 
and 2006 (n=13,611), and those diagnosed between 2007 and 2013 (n=12,845). This 
stratification was applied to carry out the Multiple Cox proportional hazards Regression to 
examine if the hazards would change. In addition, such a stratification was applied to determine 
if the Kaplan-Meier estimated survival curves would be visually modified. For those patients 
diagnosed with lung cancer between 2000 and 2006, the multivariable proportional hazards 
model revealed that only age at diagnosis, performing surgery and having an ungraded tumor 
were statistically significant predictors (95% CIs: 1.006-1.022, 1.091-1.829, and 0.495-0.813, 
respectively). On the other hand, for those patients diagnosed with lung cancer between 2007 and 
2013, the multivariable proportional hazards model demonstrated that age at diagnosis, gender, 
having a stage IV tumor, radiation and surgery were statistically significant predictors (95% CIs: 
1.005-1.027, 1.083-1.675, 0.414-0.863, 1.05-1.832, 1.262-2.498, respectively)6. Thus, the 
investigators concluded that statistically significant associations which were observed in the final 
multivariable proportional hazards model for non-stratified data could have been influenced by 
patients diagnosed in earlier years compared to those diagnosed in later years. However, overall, 
the stratification did not make a significant difference to the estimates of the multivariable 
proportional hazards model as well as to the Kaplan-Meier estimated survival curves (See Figure 
                                                 
6 Refer to Table 1 and Table 2 in the Appendix  
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1.1. and 1.2.). Thus, it was decided to report the results for the original, non-stratified data in 
order to increase the power with a larger sample. 
Figure 1.1. The K-M Estimated Survival Curve ≤2006 (this stratum includes patients 
who were diagnosed with lung cancer in 2000 through 2006).  
There are no statistically significant differences between the exposed and unexposed 
groups not controlling for confounders 
Test of Equality over Strata  
Test    Chi-Square  DF  Pr > 
Chi-Square Log-Rank 0.1208  1  0.7282  
Wilcoxon   0.0389  1  0.8437 
 -2Log(LR)   0.0100  1  0.9205 
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Figure 1.2. The K-M Estimated Survival Curve >2006 (this stratum includes patients 
who were diagnosed with lung cancer in 2007 through 2013).  
There are no statistically significant differences between two groups, however, we can 
see that overall survival time is less than in the previous stratum. 
 
Test of Equality over Strata 2007+  
Test    Chi-Square   DF   Pr > 
Chi-Square Log-Rank 0.5703   1   0.4502  
Wilcoxon   2.2248   1   0.1358  
-2Log(LR)   0.8708   1   0.3507 
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According to the Figure 2, statistically significant differences were observed between 
females and males with respect to probability of developing subsequent primary cancers over the 
155 month time period (59.75% vs. 50.4%, respectively; log-rank test: χ2= 6.0938, p=. 0.0136).  
 
Figure 2. The K-M Estimated Survival Curve comparing two gender groups. 
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According to Figure 3, statistically significant differences were observed between 
patients with stage II, III, IV tumors, and those with unknown status, with respect to probability 
of developing subsequent primary cancers over the 155 month time period (50.01% vs. 63.95% 
vs. 68.96% vs. 63.77%, respectively; log-rank test: χ2=39.8271, p=<.0001).  
Figure 3. The K-M Estimated Survival Curve comparing four stage groups. 
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According to Figure 4, statistically significant differences were observed between 
patients with grade I and II, III and IV tumors, and those with unknown status, with respect to 
probability of developing subsequent primary cancers over the 155 month time period (55.81% 
vs. 54.24% vs. 72.78%, respectively; log-rank test: χ2=36.4894, p=<.0001).  
Figure 4. The K-M Estimated Survival Curve comparing three grade groups. 
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According to Figure 5, statistically significant differences were observed between 
patients who went through a surgery as the treatment for their initial lung cancer, those who did 
not have surgery, as well as those with unknown status, with respect to probability of developing 
subsequent primary cancers over the 155 month time period (54.51% vs. 58.52%, vs. 79.34% 
respectively; log-rank test: χ2= 49.3153, p=<.0001). 
 Figure 5. The K-M Estimated Survival Curve comparing three surgery groups. 
 
